Design, synthesis and evaluation of quinoline-O-carbamate derivatives as multifunctional agents for the treatment of Alzheimer’s disease

References

• Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chételat G, Teunissen CE, Cummings J, van der Flier WM. Alzheimer’s disease. Lancet. 2021;397(10284):1577–1590.
   PubMed Web of Science ®Google Scholar
• Alzheimer’s Disease International. World Alzheimer report 2019: attitudes to dementia. London: Alzheimer’s Disease International; 2019. p. 1–13 [accessed 2019 Sep]. Available from: https://www.alz.co.uk/research/world-report-2019.
   Google Scholar
• Barnett R. Alzheimer’s disease. Lancet. 2019;393(10181):1589.
   PubMed Web of Science ®Google Scholar
• Cummings J, Lee G, Zhong K, Fonseca J, Taghva K. Alzheimer’s disease drug development pipeline: 2021. Alzheimers Dement. 2021;7(1):e12179.
   Web of Science ®Google Scholar
• Sang Z, Wang K, Dong J, Tang L. Alzheimer’s disease: updated multi-targets therapeutics are in clinical and in progress. Eur J Med Chem. 2022;238:114464.
   PubMed Web of Science ®Google Scholar
• Zhang H, Wang Y, Wang Y, Li X, Wang S, Wang Z. Recent advance on carbamate-based cholinesterase inhibitors as potential multifunctional agents against Alzheimer’s disease. Eur J Med Chem. 2022;240:114606.
   PubMed Web of Science ®Google Scholar
• Hampel H, Mesulam MM, Cuello AC, Farlow MR, Giacobini E, Grossberg GT, Khachaturian AS, Vergallo A, Cavedo E, Snyder PJ, Khachaturian ZS. The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease. Brain. 2018;141(7):1917–1933.
   PubMed Web of Science ®Google Scholar
• Francis PT. The interplay of neurotransmitters in Alzheimer’s disease. CNS Spectr. 2005;10(11 Suppl 18):6–9.
   PubMed Web of Science ®Google Scholar
• Inestrosa NC, Urra S, Colombres M. Acetylcholinesterase (AChE)–amyloid-beta-peptide complexes in Alzheimer’s disease. the Wnt signaling pathway. Curr Alzheimer Res. 2004;1(4):249–254.
   PubMedGoogle Scholar
• Li Q, Yang H, Chen Y, Sun H. Recent progress in the identification of selective butyrylcholinesterase inhibitors for Alzheimer’s disease. Eur J Med Chem. 2017;132:294–309.
   PubMed Web of Science ®Google Scholar
• Jasiecki J, Targońska M, Wasąg B. The role of butyrylcholinesterase and iron in the regulation of cholinergic network and cognitive dysfunction in Alzheimer’s disease pathogenesis. Int J Mol Sci. 2021;22(4):2033.
   PubMed Web of Science ®Google Scholar
• Forloni G, Balducci C. Alzheimer’s disease, oligomers, and inflammation. J Alzheimers Dis. 2018;62(3):1261–1276.
   PubMed Web of Science ®Google Scholar
• Ozben T, Ozben S. Neuro-inflammation and anti-inflammatory treatment options for Alzheimer’s disease. Clin Biochem. 2019;72:87–89.
   PubMed Web of Science ®Google Scholar
• Liu P, Wang Y, Sun Y, Peng G. Neuroinflammation as a potential therapeutic target in Alzheimer’s disease. Clin Interv Aging. 2022;17:665–674.
   PubMed Web of Science ®Google Scholar
• Moor LFE, Vasconcelos TRA, da R Reis R, Pinto LSS, da Costa TM. Quinoline: an attractive scaffold in drug design. Mini Rev Med Chem. 2021;21(16):2209–2226.
   PubMed Web of Science ®Google Scholar
• Tabassum R, Ashfaq M, Oku H. Current pharmaceutical aspects of synthetic quinoline derivatives. Mini Rev Med Chem. 2021;21(10):1152–1172.
   PubMed Web of Science ®Google Scholar
• Yang X, Cai P, Liu Q, Wu J, Yin Y, Wang X, Kong L. Novel 8-hydroxyquinoline derivatives targeting β-amyloid aggregation, metal chelation and oxidative stress against Alzheimer’s disease. Bioorg Med Chem. 2018;26(12):3191–3201.
   PubMed Web of Science ®Google Scholar
• Pavlidis N, Kofinas A, Papanikolaou MG, Miras HN, Drouza C, Kalampounias AG, Kabanos TA, Konstandi M, Leondaritis G. Synthesis, characterization and pharmacological evaluation of quinoline derivatives and their complexes with copper(ΙΙ) in in vitro cell models of Alzheimer’s disease. J Inorg Biochem. 2021;217:111393.
   PubMed Web of Science ®Google Scholar
• Wang XQ, Zhao CP, Zhong LC, Zhu DL, Mai DH, Liang MG, He MH. Preparation of 4-flexible amino-2-arylethenyl-quinoline derivatives as multi-target agents for the treatment of Alzheimer’s disease. Molecules. 2018;23(12):3100.
   PubMed Web of Science ®Google Scholar
• Wang Z, Hu J, Yang X, Feng X, Li X, Huang L, Chan ASC. Design, synthesis, and evaluation of orally bioavailable quinoline-indole derivatives as innovative multitarget-directed ligands: promotion of cell proliferation in the adult murine hippocampus for the treatment of Alzheimer’s disease. J Med Chem. 2018;61(5):1871–1894.
   PubMed Web of Science ®Google Scholar
• Nguyen K, Hoffman H, Chakkamparambil B, Grossberg GT. Evaluation of rivastigmine in Alzheimer’s disease. Neurodegener Dis Manag. 2021;11(1):35–48.
   PubMed Web of Science ®Google Scholar
• Sang Z, Bai P, Ban Y, Wang K, Wu A, Mi J, Hu J, Xu R, Zhu G, Wang J, et al. Novel donepezil-chalcone-rivastigmine hybrids as potential multifunctional anti-Alzheimer’s agents: design, synthesis, in vitro biological evaluation, in vivo and in silico studies. Bioorg Chem. 2022;127:106007.
   PubMed Web of Science ®Google Scholar
• Sang Z, Wang K, Bai P, Wu A, Shi J, Liu W, Zhu G, Wang Y, Lan Y, Chen Z, et al. Design, synthesis and biological evaluation of novel O-carbamoyl ferulamide derivatives as multi-target-directed ligands for the treatment of Alzheimer’s disease. Eur J Med Chem. 2020;194:112265.
   PubMed Web of Science ®Google Scholar
• Sang Z, Wang K, Shi J, Liu W, Tan Z. Design, synthesis, in-silico and biological evaluation of novel chalcone-O-carbamate derivatives as multifunctional agents for the treatment of Alzheimer’s disease. Eur J Med Chem. 2019;178:726–739.
   PubMed Web of Science ®Google Scholar
• Mesiti F, Chavarria D, Gaspar A, Alcaro S, Borges F. The chemistry toolbox of multitarget-directed ligands for Alzheimer’s disease. Eur J Med Chem. 2019;181:111572.
   PubMed Web of Science ®Google Scholar
• Sang Z, Wang K, Shi J, Liu W, Cheng X, Zhu G, Wang Y, Zhao Y, Qiao Z, Wu A, et al. The development of advanced structural framework as multi-target-directed ligands for the treatment of Alzheimer’s disease. Eur J Med Chem. 2020;192:112180.
   PubMed Web of Science ®Google Scholar
• Sang Z, Qiang X, Li Y, Yuan W, Liu Q, Shi Y, Ang W, Luo Y, Tan Z, Deng Y. Design, synthesis and evaluation of scutellarein-O-alkylamines as multifunctional agents for the treatment of Alzheimer’s disease. Eur J Med Chem. 2015;94:348–366.
   PubMed Web of Science ®Google Scholar
• Tian C, Qiang X, Song Q, Cao Z, Ye C, He Y, Deng Y, Zhang L. Flurbiprofen-chalcone hybrid Mannich base derivatives as balanced multifunctional agents against Alzheimer’s disease: design, synthesis and biological evaluation. Bioorg Chem. 2020;94:103477.
   PubMed Web of Science ®Google Scholar
• Erdogan M, Kilic B, Sagkan RI, Aksakal F, Ercetin T, Gulcan HO, Dogruer DS. Design, synthesis and biological evaluation of new benzoxazolone/benzothiazolone derivatives as multi-target agents against Alzheimer’s disease. Eur J Med Chem. 2021;212:113124.
   PubMed Web of Science ®Google Scholar
• Košak U, Brus B, Knez D, Žakelj S, Trontelj J, Pišlar A, Šink R, Jukič M, Živin M, Podkowa A, Nachon F, et al. The magic of crystal structure-based inhibitor optimization: development of a butyrylcholinesterase inhibitor with picomolar affinity and in vivo activity. J Med Chem. 2018;61(1):119–139.
   PubMed Web of Science ®Google Scholar
• Dighe SN, Deora GS, De la Mora E, Nachon F, Can S, Parat MO, Brazzolotto X, Ross BP. Discovery and structure-activity relationships of a highly selective butyrycholinesterase inhibitor by structure-based virtual screening. J Med Chem. 2016;59:7683–7689.
   PubMed Web of Science ®Google Scholar
• Liu Z, Fang L, Zhang H, Gou S, Chen L. Design, synthesis and biological evaluation of multifunctional tacrine-curcumin hybrids as new cholinesterase inhibitors with metal ions-chelating and neuroprotective property. Bioorg Med Chem. 2017;25(8):2387–2398.
   PubMed Web of Science ®Google Scholar
• Wu CF, Wang QC, Chen R, Zhou HL, Wu TT, Du Y, Zhang NN, Zhang HM, Fan ZY, Wang LL, et al. Synthesis and bioevaluation of diaryl urea derivatives as potential antitumor agents for the treatment of human colorectal cancer. Eur J Med Chem. 2022;229:114055.
   PubMed Web of Science ®Google Scholar
• Huang W, Li C, Shen Z, Zhu X, Xia B, Li C. Development of a zebrafish model for rapid drug screening against Alzheimer’s disease. J Pharm Pharmacol. 2016;4:174–185.
   Google Scholar
• Sang Z, Wang K, Xue H, Cao M, Tan Z, Liu W. Design, synthesis and evaluation of novel ferulic acid derivatives as multi-target-directed ligands for the treatment of Alzheimer’s disease. ACS Chem Neurosci. 2019;10(2):1008–1024.
   PubMed Web of Science ®Google Scholar